Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 09, 2023

CDK4/6 Inhibition Triggers ICAM1-Driven Immune Response and Sensitizes LKB1-Mutant Lung Cancer to Immunotherapy

Nature Communications

 

Additional Info

Disclosure statements are available on the authors' profiles:

Nature Communications
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
Nat Commun 2023 Mar 04;14(1)1247, X Bai, ZQ Guo, YP Zhang, ZZ Fan, LJ Liu, L Liu, LL Long, SC Ma, J Wang, Y Fang, XR Tang, YJ Zeng, X Pan, DH Wu, ZY Dong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading